WEBULL
WebtradeDownload

The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status

Simply Wall St · 2d ago
  • In August 2026, Celcuity Inc. reported a wider Q2 net loss of US$78.86 million and higher basic loss per share, while securing FDA approval and a preferred Category 1 NCCN guideline recommendation for Revtopik in HR-positive, HER2-negative advanced breast cancer.
  • Alongside the deeper losses, the combination of strong Phase 3 efficacy data and rapid guideline endorsement for Revtopik materially reshapes how Celcuity’s pipeline can translate into future commercial activity.
  • We’ll now examine how FDA approval and preferred guideline status for Revtopik could influence Celcuity’s earlier investment narrative built around future gedatolisib potential.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Celcuity Investment Narrative Recap

To own Celcuity today, you have to believe that gedatolisib’s transition from a pure R&D asset to an approved drug can eventually offset heavy current losses and funding needs. The Q2 net loss of US$78.86 million underlines how dependent the story is on successful Revtopik commercialization as the key near term catalyst, while the primary risk now shifts to execution on launch, guideline driven uptake and payer access rather than binary trial or approval events.

The most relevant recent announcement is the FDA approval of Revtopik and its preferred Category 1 NCCN guideline status for HR positive, HER2 negative advanced breast cancer. This moves the discussion from hypothetical future labels to an active, reimbursable product that could begin generating initial revenue once commercial shipments start in late Q3 2026, directly intersecting with concerns about rising losses and the company’s ability to justify its expanding cost base.

However, investors should also weigh how Celcuity’s accelerating cash burn and reliance on sizeable debt and convertible financing could affect future flexibility if Revtopik uptake lags expectations and...

Read the full narrative on Celcuity (it's free!)

Celcuity's narrative projects $817.9 million revenue and $267.5 million earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

Uncover how Celcuity's forecasts yield a $161.09 fair value, a 75% upside to its current price.

Exploring Other Perspectives

CELC 1-Year Stock Price Chart
CELC 1-Year Stock Price Chart

Before this news, the most cautious analysts were assuming about US$535.0 million of revenue and only US$22.0 million of earnings by 2029, so compared with the consensus narrative they paint a far more constrained path to value creation, and you can see how the latest approval might challenge that view while also highlighting just how differently reasonable people can size the same opportunity.

Explore 4 other fair value estimates on Celcuity - why the stock might be worth just $160.64!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.